BeStock  
Stocks › Biotechnology › CLYM

Climb Bio CLYM

US equityMarket cap rank #3605Biotechnology
$10.71 +$0.03 (+0.28%)
Market closed · Oct 8, 7:20 am ET · Last extended-hours $10.71 0.00%
Open$10.43
Prev close$10.68
Day range$10.34 – $10.95
Volume755.8K
Market cap$615.14M
P/E (TTM)–
Dividend yield–

CLYM Stock News

Headlines matching Climb Bio or the CLYM ticker, most recent first.

  • H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 PositiveMarket news · 8 Sep 2026 · Direct mention
  • Truist Financial Maintains Climb Bio(CLYM.US) With Buy RatingMarket news · 4 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40Market news · 4 Sep 2026 · Direct mention
  • B. Riley Securities Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 PositiveMarket news · 4 Sep 2026 · Direct mention
  • RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23Market news · 8 Aug 2026 · Direct mention
  • Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18Market news · 7 Aug 2026 · Direct mention
  • Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25Market news · 7 Aug 2026 · Direct mention
  • BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20Market news · 7 Aug 2026 · Direct mention
  • RBC Capital Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $23Market news · 3 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $24 PositiveMarket news · 24 Aug 2026 · Direct mention
  • Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $20Market news · 19 Aug 2026 · Direct mention
  • William Blair Maintains Climb Bio(CLYM.US) With Buy RatingMarket news · 19 Aug 2026 · Direct mention
  • Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $25Market news · 13 Aug 2026 · Direct mention
  • Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23Market news · 30 Jul 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI) and Climb Bio (CLYM)TipRanks · 14 Jul 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on CLYM.

Leave a comment

Scroll to Top